Standardized TIL Expansion and IP-10 Biomarker for Refractory Melanoma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for double-refractory metastatic melanoma, including immune checkpoint inhibitors and targeted therapies, have limited efficacy and are associated with significant toxicity, and there is a need to standardize tumor infiltrating lymphocyte (TIL) production and identify suitable patient populations for TIL therapy.
Innovation Solution
Administering a therapeutically effective population of tumor infiltrating lymphocytes (TILs) to patients with double-refractory metastatic melanoma, combined with a biomarker-based approach using IP-10 to predict treatment efficacy, and a method for TIL expansion involving closed-system processing and expansions with IL-2 and antigen presenting cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immune checkpoint inhibitors and targeted therapies are used to treat double-refractory metastatic melanoma, then treatment options are available, but efficacy is limited and toxicity is significant
Solution Approach 1:
The patent segments the treatment approach by using adoptive cell transfer with tumor-infiltrating lymphocytes (TILs) as a distinct therapeutic modality separate from immune checkpoint inhibitors and targeted therapies. This allows selection of patients who have exhausted other treatment options, thereby reducing cumulative toxicity while maintaining efficacy potential in refractory cases
Solution Approach 2:
The patent changes the therapeutic parameter from pharmacological agents (drugs) to biological agents (living immune cells). TIL therapy represents a fundamental parameter change from chemical therapy to cellular therapy, offering a different mechanism of action that may be effective where pharmacological approaches have failed, while potentially reducing certain types of drug-related toxicity
2Reliability
If TIL therapy is administered to patients with double-refractory metastatic melanoma, then clinical responses can be achieved, but standardized production methods are needed
Solution Approach 1:
The patent implements preliminary action by establishing standardized protocols for TIL isolation, expansion, and quality control before clinical administration. The method includes predefined criteria for patient selection, tumor tissue processing, lymphocyte culture conditions, and release criteria, ensuring consistent production quality before the therapy is administered to patients
Solution Approach 2:
The patent applies parameter changes by defining specific numerical parameters for TIL production including cell density ranges, expansion fold-changes, viability thresholds, and contaminant limits. These quantified parameters transform the manufacturing process from an artisanal procedure to a standardized industrial process with controlled variables
3Adaptability or versatility
If multiple prior treatments are administered before TIL therapy, then refractory cases are addressed, but treatment complexity increases
Solution Approach 1:
The patent applies inversion by reversing the traditional treatment sequence where TIL therapy is used not as a first-line treatment but specifically after patients have failed multiple prior therapies. This inverted approach targets the refractory population who have exhausted standard options, simplifying the decision algorithm by clearly defining exclusion criteria based on prior treatment history
Data Source
AI summary
Methods of treating melanomas refractory to other therapies using tumor infiltrating lymphocytes are disclosed. Also disclosed is the use of IP-10 as a biomarker for predicting treatment efficacy.